Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
Released: Feb 4, 2016
Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.
